224 related articles for article (PubMed ID: 22453004)
1. Effect of direct renin inhibitor, aliskiren, on peripheral blood monocyte subsets and myocardial salvage in patients with primary acute myocardial infarction.
Ozaki Y; Imanishi T; Tanimoto T; Kashiwagi M; Tsujioka H; Sougawa H; Orii M; Shiono Y; Shimamura K; Ishibashi K; Komukai K; Ino Y; Kitabata H; Akasaka T
Circ J; 2012; 76(6):1461-8. PubMed ID: 22453004
[TBL] [Abstract][Full Text] [Related]
2. Effect of direct renin inhibitor on left ventricular remodeling in patients with primary acute myocardial infarction.
Ozaki Y; Imanishi T; Tanimoto T; Teraguchi I; Nishiguchi T; Orii M; Shiono Y; Shimamura K; Yamano T; Ino Y; Yamaguchi T; Kubo T; Akasaka T
Int Heart J; 2014; 55(1):17-21. PubMed ID: 24463924
[TBL] [Abstract][Full Text] [Related]
3. Does direct inhibition bring direct benefit?
Abe S; Taguchi I; Inoue T
Circ J; 2012; 76(6):1326. PubMed ID: 22739081
[No Abstract] [Full Text] [Related]
4. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K
Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458
[TBL] [Abstract][Full Text] [Related]
5. Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists.
Ito T; Ishikawa E; Fujimoto N; Okubo S; Ito G; Ichikawa T; Nomura S; Ito M
Clin Exp Hypertens; 2014; 36(7):497-502. PubMed ID: 24433061
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Bomback AS; Toto R
Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
[TBL] [Abstract][Full Text] [Related]
8. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction.
Tsujioka H; Imanishi T; Ikejima H; Kuroi A; Takarada S; Tanimoto T; Kitabata H; Okochi K; Arita Y; Ishibashi K; Komukai K; Kataiwa H; Nakamura N; Hirata K; Tanaka A; Akasaka T
J Am Coll Cardiol; 2009 Jul; 54(2):130-8. PubMed ID: 19573729
[TBL] [Abstract][Full Text] [Related]
9. Aliskiren and valsartan combination therapy for the management of hypertension.
Epstein BJ
Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
[TBL] [Abstract][Full Text] [Related]
10. Update on role of direct renin inhibitor in diabetic kidney disease.
Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
[TBL] [Abstract][Full Text] [Related]
11. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
Doulton TW; MacGregor GA
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
[TBL] [Abstract][Full Text] [Related]
12. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
13. Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.
Kwakernaak AJ; Roksnoer LC; Lambers Heerspink HJ; van den Berg-Garrelds I; Lochorn GA; van Embden Andres JH; Klijn MA; Kobori H; Danser AH; Laverman GD; Navis GJ
PLoS One; 2017; 12(1):e0169258. PubMed ID: 28118402
[TBL] [Abstract][Full Text] [Related]
14. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
15. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
16. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
17. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
[TBL] [Abstract][Full Text] [Related]
19. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ; Desai A; Gimpelewicz C; Kandra A; Reimund B; Rattunde H; Armbrecht J;
Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387
[TBL] [Abstract][Full Text] [Related]
20. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
